Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Lymphoma, T-Cell 2Oligodendroglioma 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Inflammatory Breast Neoplasms 1Immunoblastic Lymphadenopathy 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 69Radiotherapy 30Bevacizumab 24Carboplatin 13pembrolizumab 12Radiation 11Carmustine 8Irinotecan 7temsirolimus 6Surgical Procedures, Operative 6Radiosurgery 6Erlotinib Hydrochloride 6atezolizumab 5Vorinostat 5Sirolimus 5Radiotherapy, Intensity-Modulated 5Nivolumab 5Lomustine 5Everolimus 5fludarabine 4Radiotherapy, Conformal 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Aminolevulinic Acid 4tipifarnib 3Sorafenib 3Paclitaxel 3IL13-PE38 3Granulocyte-Macrophage Colony-Stimulating Factor 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Glioblastoma × Depsipeptides × Clear all
NCT00085540 2017-01-02

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

National Cancer Institute (NCI)

Phase 1/2 Completed
50 enrolled 6 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡